Dare Bioscience, Inc. — Q3 2022 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2022. The unaudited statements cover a clinical-stage women’s health biopharmaceutical company; results are not necessarily indicative of full-year performance.
Business context
Daré’s portfolio targets contraception, fertility, and vaginal and sexual health. Its FDA-approved product, XACIATO, was licensed to Organon for commercialization. The company expects to remain primarily focused on research and development and relies on collaborators, grants, and external financing.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $10.0 million | $0 |
| Operating expenses | $7.14 million | $12.67 million | $25.15 million | $29.53 million |
| Operating loss | $7.14 million | $12.67 million | $15.15 million | $29.53 million |
| Net loss | $7.02 million | $12.67 million | $15.00 million | $29.15 million |
| Loss per share, basic and diluted | $0.08 | $0.18 | $0.18 | $0.45 |
The $10.0 million nine-month revenue was the one-time, nonrefundable Organon upfront license payment, received in July; no revenue was recorded in Q3. No gross margin is reported for the period. Q3 R&D expense fell 57% year over year, to $4.46 million, primarily reflecting lower costs for Sildenafil Cream and Ovaprene, completion of XACIATO’s Phase 3 trial, and lower spending on other programs. Q3 G&A rose 20%, to $2.65 million, mainly on professional services. For the nine months, R&D declined 27% and G&A increased 35% year over year.
At September 30, cash and cash equivalents were $40.39 million, total assets $50.38 million, total liabilities $24.03 million, and working capital approximately $26.7 million. Accumulated deficit was $125.1 million. Cash used in operating activities was $12.19 million for the nine months, versus $18.85 million in 2021; investing cash outflow was $0.06 million. Financing provided $1.34 million, compared with $59.84 million in 2021, largely reflecting the prior-year equity issuance. The filing reports lease liabilities but no other borrowing balance. Cash includes grant funds restricted to DARE-LARC1 development: deferred grant funding was $14.84 million.
Material changes, outlook, and risks
- Liquidity and going concern: Management states that current cash is insufficient for working capital and other liquidity needs for at least 12 months from issuance of the statements, raising substantial doubt about the company’s ability to continue as a going concern. It expects operating losses and negative operating cash flow in 2022 and 2023 and says substantial additional capital is needed. Potential funding sources include equity, debt, grants, collaborations, and strategic arrangements; availability and terms are uncertain, and equity financing may dilute shareholders.
- Management outlook: The company expected 2022 G&A to increase approximately 25% versus 2021 and R&D to remain approximately flat versus 2021, though R&D spending was expected to be lower than previously anticipated. R&D is expected to remain significant as clinical-stage programs advance. No specific revenue forecast was provided.
- XACIATO: First U.S. commercial sale was expected in the first half of 2023. Daré is eligible for a $2.5 million first-sale milestone, up to $180 million in additional potential milestones, and tiered double-digit royalties. Organon may terminate the agreement after its first anniversary on 120 days’ notice. Daré must provide interim product supply and regulatory support.
- Pipeline and subsequent events: In October 2022, the FDA approved the IDE for Ovaprene’s pivotal Phase 3 study; recruitment was targeted for mid-2023, and Daré expected a $1.0 million milestone payment. Daré reported positive topline DARE-HRT1 results in October, while topline data from the Sildenafil Cream Phase 2b study were targeted for Q2 2023. These are post-quarter developments, not Q3 results.
- Other obligations and risks: Daré had paid $5.0 million of its $5.5 million Ovaprene Phase 3 CRADA commitment; the remaining $0.5 million was due in Q2 2023. Key risks include clinical and regulatory failure or delay, manufacturing and collaborator execution, product market acceptance and reimbursement, competition, and the ability to raise capital. The filing also highlights potential effects of drug-pricing legislation, including the Inflation Reduction Act.
Most important facts for investors to verify
- Whether Daré secures sufficient financing to address the stated liquidity shortfall, and the resulting dilution or other financing terms.
- How much reported cash is practically available for general operations given grant-use restrictions, and whether burn rates or program priorities change.
- Progress, timing, costs, and data for the Ovaprene pivotal study and Sildenafil Cream trial, including FDA requirements and any milestone obligations.
- Organon’s XACIATO launch timing, commercial performance, supply transition, and the conditions for royalties and milestone payments.
- Whether post-quarter developments and stated timelines translate into regulatory progress, commercial revenue, and adequate runway.